A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders

United European Gastroenterology Journal

Volumn 1, Issue 5, 2013, Pages 385-393

  Lahner, Edith ^a   Bellentani, Stefano ^b,f   De Bastiani, Rudy ^b   Tosetti, Cesare ^b,j   Cicala, Michele ^c   Esposito, Gianluca ^a   Arullani, Paolo ^d   Annibale, Bruno ^a   Beccari, Gizela ^e   Benedetto, Edoardo ^e   Bertolusso, Luciano ^e   Bozzani, Alberto ^e   Bruschelli, Carla ^e   Casamassima, Carlo ^e   Chiaritti, Alberto ^e   Ciaccia, Angela ^g   Coltraro, Giovanni ^e   Cottone, Carmelo ^e   De Bastiani, Rudi ^h   De Polo, Manuela ^e   Disclafani, Giuseppe ^e   Fornoni, Wilma ^e   Fracasso, Pierluigi ^e   Grattagliano, Ignazio ^g   Napoli, Luigi ^e   Nebiocolombo, Cristina ^e   Sanna, Guido ^e   Scorpiniti, Anna ⁱ   Ubaldi, Enzo ^e   Vetrano, Salvatore ^e   Zamparella, Maria ^e   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Italian Society of Gastroenterology (SIGE)   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d Liver and Pancreatic Diseases   (Italy)

^e NONE   (Italy)

^f Servizio Psichiatrico di Diagnosi e Cura Modena Centro   (Italy)

^g NONE   (Italy)

^h NONE   (Italy)

ⁱ NONE   (Italy)

^j Hospital of Porretta Terme   (Italy)

more..

Author keywords

Complementary and alternative medicine; Functional dyspepsia; Functional gastrointestinal disorders; Irritable bowel syndrome; Treatment

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANXIOLYTIC AGENT; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; LAXATIVE; PREBIOTIC AGENT; PROBIOTIC AGENT; PROKINETIC AGENT; PROTON PUMP INHIBITOR; SPASMOLYTIC AGENT;

ABSENCE OF SIDE EFFECTS; ACUPUNCTURE; ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE SURVEY; HOMEOPATHY; HUMAN; INTERVIEW; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; VITAMIN SUPPLEMENTATION;

EID: 85006223377     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640613499567     Document Type: Article

References (48)

1. Mayer EA. Irritable bowel syndrome. N Engl J Med 2008; 358: 1692-1699.
2. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-1479.
3. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-1390.
4. Lea R and Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001; 19: 643-653.
5. Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep 2009; 11: 265-269.
6. Ohman L and Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-173.
7. Longstreth GF, Thomspon WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491.
8. Camilleri M and Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009; 41: 854-862.
9. Chang JY and Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends Pharmacol Sci 2010; 31: 326-334.
10. Brun R and Kuo B. Functional dyspepsia. Therap Adv Gastroenterol 2010; 3: 145-164.
11. Lacy BE, Talley NJ, Locke GR, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36: 3-15.
12. Whitehead WE, Levy RL, Von Korff M, et al. The usual medical care for irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 1305-1315.
13. Nahin RL, Pontzer CH and Chesney MA. Racing toward the integration of complementary and alternative medicine: A marathon or a sprint? Health Aff 2005; 24: 991-993.
14. Spanier JA, Howden CW and Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163: 265-274.
15. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001; 135: 262-268.
16. Langmead L and Rampton DS. Herbal treatment in gastrointestinal and liver disease - benefits and dangers. Aliment Pharmacol Ther 2001; 15: 1239-1252.
17. Hussain Z and Quigley EMM. Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 465-471.
18. Ernst E. The role of complementary and alternative medicine. BMJ 2000; 321: 1133-1135.
19. Kong SC, Hurlstone DP, Pocock CY, et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005; 39: 138-141.
20. Stake-Nilsson K, Hultcrantz R, Unge P, et al. Complementary and alternative medicine used by persons with functional gastrointestinal disorders to alleviate symptom distress. J Clin Nurs 2012; 21: 800-808.
21. Kav T. Use of complementary and alternative medicine: A survey in Turkish gastroenterology patients. BMC Complement Altern Med 2009; 9: 41.
22. Van Tilburg MA, Palsson OS, Levy RL, et al. Complementary and alternative medicine use and cost in functional bowel disorders: A six month prospective study in a large HMO. BMC Complement Altern Med 2008; 8: 46.
23. Carmona-Sanchez R and Tostado-Fernandez FA. Prevalence of use of alternative and complementary medicine in patients with irritable bowel syndrome, functional dyspepsia and gastroesophageal reflux disease. Rev Gastroenterol Mex 2005; 70: 393-398.
24. Lim B, Manheimer E, Lao I, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; (5): CD005111.
25. Webb AN, Kukuruzovic R, Catto-Smith AG, et al. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007; (4): CD005110.
26. Hussain Z and Quigley EMM. Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 465-471.
27. Spanier JA, Howden CW and Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163: 265-274.
28. Langmead L and Rampton DS. Herbal treatment in gastrointestinal and liver disease - benefits and dangers. Aliment Pharmacol Ther 2001; 15: 1239-1252.
29. Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel sindrome. BMC Gastroenterology 2009; 9: 15.
30. Simren M, Abrahamsson H, Bosaeus I, et al. Nutritional aspects in patients with functional gastrointestinal disorders and motor dysfunction in the gut. Working team report of the Swedish Motility Group (SMog). Digest Liver Dis 2007; 39: 495-504.
31. Liu J, Yang M, Liu Y, et al. Herbal medicines for treatment of irritable bowel syndrom. Cochrane Database Syst Rev 2006; (1): CD004116.
32. Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled multi-centre trial. Aliment Pharmacol Ther 2004; 19: 271-279.
33. Soo S, Moayyedi P, Deeks JJ, et al. Psychological intervention for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; (2): CD002301.
34. Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial. Gut 2004; 53: 1459-1464.
35. Drossman DA, Talley NJ, Whitehead WE, et al. The Rome II Modular Questionnaire: investigator and respondent forms. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG and Whitehead WE (eds) Rome II. The functional gastrointestinal disorders. Vol. 2, McLean, VA, USA: Degnon Associates, pp. 669-678.
36. Paterson WG, Thompson WG, Vanner SJ, et al. Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants. CMAJ 1999; 161: 154-160.
37. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131.
38. Camilleri M and Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 187-194.
39. Weizman AV, Ahn E, Thanabalan R, et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 342-349.
40. Eisenberg DM, Kessler RC, Van Rompay MI, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: Results from a national survey. Ann Intern Med 2001; 135: 344-351.
41. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998; 279: 1548-1553.
42. Druss BG and Rosenheck RA. Association between use of unconventional therapies and conventional medical services. JAMA 1999; 282: 651-656.
43. Bytzer P. Dyspepsia as an adverse effect of drugs. Best Pract Res Clin Gastroenterol 2010; 24: 109-120.
44. Enck P, Horing B, Weimer K, et al. Placebo responses and placebo effects in functional bowel disorders. Eur J Gastroenterol Hepatol 2012; 24: 1-8.
45. Licata A, Macaluso FS and Craxı A. Herbal hepatotoxicity: A hidden epidemic. Intern Emerg Med 2013; 8: 13-22.
46. Angell M and Kassirer JP. Alternative medicine: the risks of untested und unregulated remedies (editorial). N Engl J Med 1998; 339: 839-841.
47. Posadzki P, Alotaibi A and Ernst E. Adverse effects of homeopathy: a systematic review of published case reports and case series. Int J Clin Pract 2012; 66: 1178-1188.
48. Heading R, Bardhan K, Hollerbach S, et al. Systematic review: the safety and tolerability of pharmacological agents for treatment of irrititable bowel syndrome - a European perspective. Aliment Pharmacol Ther 2006; 24: 207-236.